Lipid nanoparticles have evolved from specialized nucleic-acid carriers into clinically validated delivery platforms. Yet liver-dominant biodistribution, non-specific uptake, repeat-dose immune responses, and limited extrahepatic delivery continue to constrain broader therapeutic use. This webinar examines how LNP 2.0 is shifting the field toward increasingly selective, programmable, and biologically informed delivery.
Lipid nanoparticles have become foundational to the delivery of nucleic-acid therapeutics, but their clinical success has also made their limitations more visible. Preferential liver accumulation, phagocytic-cell uptake, limited extrahepatic access, and immune responses to repeat dosing continue to restrict how broadly these platforms can be applied.
LNP 2.0 marks a shift from broadly distributed delivery vehicles toward increasingly selective systems shaped by next-generation lipid chemistry, ligand-receptor targeting, protein-corona control, biodistribution engineering, route-of-administration design, and data-guided formulation optimization.
As these capabilities advance, the strategic question is no longer whether selective LNP delivery is technically possible, but which platforms are becoming biologically credible, translationally relevant, and commercially meaningful across immune-cell targeting, regenerative medicine, genome engineering, pulmonary delivery, and other high-value applications.
Exploring how conventional LNP success has exposed delivery limitations, including liver bias, non-specific uptake, and repeat-dose immune responses, with anti-PEG antibodies increasing in ~33% of recipients.
Comparing composition, ligand, protein-corona, and route-based targeting approaches, with preclinical platforms achieving up to ~93% hepatocyte transfection and ~65% lung endothelial-cell targeting.
Exploring advances in lipid chemistry, surface engineering, hepatic de-targeting, endosomal escape, and immune evasion, as conventional LNPs may deliver only ~1–2% of internalized RNA cytosolically.
Assessing the shift toward tissue, receptor, and cell-selective delivery, with emerging platforms demonstrating ~40% T-cell and >60% HSPC/HSC targeting in preclinical studies.
Mapping opportunities across immune-cell targeting, pulmonary delivery, genome engineering, regenerative medicine, CNS access, and responsive delivery, with LNP-CRISPR programs achieving up to ~87% target-protein reduction after single dose.
Exploring how selective LNPs are expanding beyond mRNA to siRNA, CRISPR, circular and self-amplifying RNA, and RNPs, with next-generation platforms showing potential for ~10× dose-sparing.
Demonstrating how integrated scientific, technology, IP, competitive, and external-innovation intelligence can support platform assessment, opportunity prioritization, partner evaluation, licensing strategy, and build-versus-access decisions.
Tanu Kapoor has 10+ years of experience in strategic consulting, intellectual property intelligence, and biopharma innovation. She specializes in technology assessment, competitive intelligence, and strategy development, helping global healthcare organizations identify opportunities, navigate complex IP landscapes, and strengthen R&D pipelines. Her work bridges science, business, and intellectual property to drive innovation and sustainable growth in healthcare.
View LinkedIn profile
Damini Goyal has 6+ years of experience in strategic consulting and healthcare intelligence. She specializes in innovation ecosystem mapping, competitive intelligence, emerging technology assessment, and IP-driven strategy, helping global biopharma organizations navigate complex scientific and market landscapes. Her work combines deep domain expertise with structured problem-solving to uncover opportunities, guide R&D and partnership decisions, and drive sustainable growth across therapeutic areas.
View LinkedIn profileDiscover how organ, tissue, and cell-selective platforms are expanding the therapeutic reach of lipid nanoparticles and reshaping the future of advanced delivery.
